Bot Detector
IJPC Seal
Download FREE Sample Issue or Article
LEARN MORE
Subscribe Today
A subscription to IJPC provides on-line access to full-text, full-color, printable PDF copies of your subscribed issues, individual articles, and purchased archives.

Formulation and Stability Evaluation of Extemporaneously Prepared Atenolol Capsules from Crushed Atenolol Tablets

Author(s):  Zaid Abdel Naser, Malkieh Numan, Kharoaf Maher, Ghoush Abeer Abu, Al-Ramahi Rowa'

Issue:  Jul/Aug 2012 - Volume 16, Number 4
View All Articles in Issue

Page(s):  342-346

Formulation and Stability Evaluation of Extemporaneously Prepared Atenolol Capsules from Crushed Atenolol Tablets Page 1
Formulation and Stability Evaluation of Extemporaneously Prepared Atenolol Capsules from Crushed Atenolol Tablets Page 2
Formulation and Stability Evaluation of Extemporaneously Prepared Atenolol Capsules from Crushed Atenolol Tablets Page 3
Formulation and Stability Evaluation of Extemporaneously Prepared Atenolol Capsules from Crushed Atenolol Tablets Page 4
Formulation and Stability Evaluation of Extemporaneously Prepared Atenolol Capsules from Crushed Atenolol Tablets Page 5

Download in electronic PDF format for $75

Abstract:  The purpose of this study was to formulate a 25-mg atenolol capsule starting from a commercial 100-mg atenolol tablet, given the fact that this strength is not available in Palestine and also because 50-mg atenolol tablets failed the splitting uniformity test of the European Pharmacopoeia, and to evaluate the chemical stability and dissolution behavior of the obtained capsules so as to ensure a high-quality product. A high-performance liquid chromatographic system was used for the analysis and quantification of atenolol in the samples studied. Samples of atenolol for analysis were prepared as reported by the United States Pharmacopeia monograph. Disintegration and dissolution tests were performed according to the United States Pharmacopeia. The high-performance liquid chromatography assay indicated that the 25-mg atenolol capsules were stable for four months when stored at ambient temperature conditions. The disintegration time for all atenolol capsules was within the United States Pharmacopeia limits of 15 minutes. Atenolol release profile showed that approximately 90% of atenolol dissolved after 10 minutes. This study is important for patients who need to take one half of a 50-mg tablet, but for whom the splitting process doesn’t give equal halves, and also for modifying the dose for patients with renal or hepatic problems. Therefore, it is possible for the community pharmacist to crush atenolol 100-mg tablets and refill them in new capsules with each containing a precise amount of atenolol, calculated according to body surface area and kidney and liver functions without affecting the chemical stability of the active ingredient nor its dissolution profile and also have a cost effective dosage form.

Related Keywords: Abdel Naser Zaid, PhD, Numan Malkieh, Maher Kharoad, Abeer Abu Ghoush, MS, Rowa' Al-Ramahi, formulation, atenolol, beta-blocker, hypertension, high blood pressure, arrhythmias, angina pectoris, myocardial infarction, heart attack, stability

Related Categories: FORMULATIONS, PEER-REVIEWED, STABILITIES, COMPATIBILITIES, QUALITY CONTROL, CARDIOLOGY

Printer-Friendly Version



Related Articles from IJPC
Title/Author
(Click for Abstract / Details / Purchase)
Issue/​Page
View/Buy
Formulation and Stability Evaluation of Extemporaneously Prepared Atenolol Capsules from Crushed Atenolol Tablets
Zaid Abdel Naser
, Malkieh Numan, Kharoaf Maher, Ghoush Abeer Abu, Al-Ramahi Rowa'
Jul/Aug 2012
Pg. 342-346

Atenolol 25-, 50-, or 100-mg Capsules
Allen Loyd V Jr
Jan/Feb 2015
Pg. 60

Atenolol 1 mg/mL or 5 mg/mL in SyrSpend SF pH4
Allen Loyd V Jr
May/Jun 2018
Pg. 233

Stability of Atenolol, Clonazepam, Dexamethasone, Diclofenac Sodium, Diltiazem, Enalapril Maleate, Ketoprofen, Lamotrigine, Penicillamine-D, and Thiamine in SyrSpend SF PH4 Oral Suspensions
Polonini HC
, Loures S, Lima LC, Ferreira AO, Brandão MA
Mar/Apr 2016
Pg. 167-174

Formulation Development and Stability Testing of Extemporaneous Suspension Prepared From Dapsone Tablets
Kaila Nitin
, El-Ries Mohamed, Riga A, Alexander Kenneth S, Dollimore D
May/Jun 2003
Pg. 233-239

Short-Term Stability of Atenolol in Oral Liquid Formulations
Patel Dipali
, Doshi Dharmesh H, Desai Archana
Nov/Dec 1997
Pg. 437-439

Preparation and Stability Evaluation of Extemporaneous Oral Suspension of Valsartan Using Commercially Available Tablets
Zaid Abdel Naser
, Assali Mohyeddin, Qaddomi Aiman, Ghanem Mashhour, Zaaror Yara Abu
Mar/Apr 2014
Pg. 169-174

Compounded Beta-blocker Nasal Spray for Treatment of Acute Migraine: A New Therapeutic Modality
Hagan John C III
, Everett Eric, Chamberlain Tyler
May/Jun 2020
Pg. 194-197

Formulation, Physical Stability, and the Clinical Effectiveness of Extemporaneous Ivermectin Oral Solution
Zaid Abdel-Naser
, Zaaror Yara Abu, Qaddumi Aiman, Ratrout Ala, Ahmad Ayda, Hamad Emad, Kittana Naim
Nov/Dec 2021
Pg. 523-527

Stability Issues for Compounding Extemporaneously Prepared Oral Formulations for Pediatric Patients
Schotik Debora
Jan/Feb 2001
Pg. 9-12

A Compendium of Compounding Agents and Formulations, Part 5: Timolol and Beta-glucans
Riepl Mike
Sep/Oct 2022
Pg. 364-368

Labetalol 50-mg Capsules
Allen Loyd V Jr
May/Jun 2013
Pg. 233

Y-site Physical Compatibility of Beta-blocker Infusions with Intensive Care Unit Admixtures
Foushee Jaime A
, Meredith Pmichaele, Fox Laura M, Grace EdwardE
Jul/Aug 2016
Pg. 328-332

Rice Bran Oil: Preparation and Evaluation of Novel Liquisolid and Semisolid Formulations
Ammar Hussein O
, Al-Okbi Sahar Y, Mostafa Dina M, Helal Amr M
Nov/Dec 2012
Pg. 516-523

Chemical Stability of Extemporaneously Compounded Omeprazole Formulations: A Comparison of Two Methods of Compounding
Garg Sanjay
, Svirskis Darren, Al-Kabban Majid, Farhan Samer, Komeshi Mohammed, Lee Jacky, Liu Quincy, Naidoo Sacha, Kairuz Therese
May/Jun 2009
Pg. 250-253

Formulation and In Vitro Evaluation of a Ramipril Entrapped in a Microsponge-based Drug-delivery System
Taghi Hassanien Sagban
, Abdulbaqi Mustafa R, Samein Laith Hamza, Rahmani Maha H Philip
Jul/Aug 2023
Pg. 340-346

Infantile Hemangiomas, Part 2: Topical Treatment with Beta Blockers
Zur Eyal
Nov/Dec 2011
Pg. 458-463

Atenolol 2-mg/mL Oral Liquid
Allen Loyd V Jr
May/Jun 2004
Pg. 215

Stability of Sotalol Hydrochloride in Extemporaneously Prepared Oral Suspension Formulations
Sidhom Madiha B
, Rivera Nadya, Almoazen Hassan, Taft David R, Kirschenbaum Harold L
Sep/Oct 2005
Pg. 402-406

Formulation, Evaluation, and Characterization of Ibuprofen Nanocrystals Tablets with Conventional Market Product
Chauhan Nikita N
, Patel Jayvadan K
Jan/Feb 2023
Pg. 60-71

Return to Top